Deals
In announcing that Novartis AG is exploring spinning off its Alcon eye-care business, Novartis CEO Joseph Jimenez acknowledged that Alcon has made progress in the…
Read MoreIn October, OIS partnered with EyeQ Research to launch the OIS Index, a composite of ophthalmic growth stocks, to track the investment performance of our…
Read More
Two weeks ago, we began reviewing collaborations between ophthalmic start-ups and institutions or groups that traditionally haven’t been involved in developing medical technology, such as…
Read More
So when does a rumor cease being a rumor and become a reality? It remains to be seen whether all the recent and persistent rumors…
Read More
The OIS Index closed at 962.42 on Tuesday, a week after Donald Trump’s election. Here’s how the collection of 29 publicly traded ophthalmology companies fared…
Read More
The past year has witnessed the formation of several collaborations between ophthalmic start-ups and institutions or groups that traditionally haven’t been involved in developing medical…
Read More
Recent positive reports about two FDA-approved corneal inlays may yet give this market sector a boost heading into 2017. Irvine, CA-based AcuFocus was the first…
Read More
At last month’s OIS@AAO, we introduced the OIS Index. To learn more about its origins and intent, listen to this OIS Podcast interview. By Michael…
Read More
Now that Regeneron has announced that its rinucumab-Eylea (aflibercept) combination treatment for wet age-related macular degeneration (AMD) failed to meet the primary endpoint of a…
Read More
The evolution of the ophthalmology sector continued with last week’s news that Johnson & Johnson would pay $4.3 billion to acquire Abbott Medical Optics, the…
Read More
The string of approvals and acquisitions in the microinvasive glaucoma surgery space has been one of ophthalmology’s more promising stories. The news shone a bright…
Read More
Biotechnology company Biogen (Cambridge, MA) recently committed $20 million into a collaboration with the University of Pennsylvania to co-develop gene therapies using next-generation adeno-associated virus…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")